Bioxytran (BIXT) Total Debt Growth (3y) (2013 - 2026)
Bioxytran (BIXT) Total Debt Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.08% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.52% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -22.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.30% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.76% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -45.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.44% |
| Dec 31, 2025 | -44.38% |
| Sep 30, 2025 | -37.00% |
| Jun 30, 2025 | -76.64% |
| Dec 31, 2024 | -52.51% |
| Mar 31, 2024 | 34.39% |
| Sep 30, 2023 | 519.03% |
| Mar 31, 2021 | 338.21% |
| Sep 30, 2020 | 17.52% |
| Jun 30, 2018 | -38.97% |
| Mar 31, 2018 | -64.31% |
| Dec 31, 2017 | -41.52% |
| Sep 30, 2017 | -41.52% |
| Jun 30, 2017 | 0.00% |
| Mar 31, 2017 | 71.00% |
| Dec 31, 2016 | -33.50% |
| Sep 30, 2016 | -64.31% |
| Jun 30, 2016 | 0.00% |
| Mar 31, 2016 | -46.14% |
| Dec 31, 2015 | -41.52% |